Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sabril's Approval With REMS No Surprise, But May Provide Marketing Advantage

This article was originally published in The Pink Sheet Daily

Executive Summary

Periodic vision testing and a restricted distribution program will be required for Lundbeck's spasticity agent.

You may also be interested in...

Specialty Pharmacies Could Be Selling Point If FDA Approves Tasimelteon

A Nov. 14 advisory committee gave near-unanimous support for Vanda’s sleep disorder drug on questions about its indication, endpoints, efficacy and safety.

FDA Grades Itself Highly In Reports On Safety Of Imported Products And Marketed Drugs

As Congressional markups of user fee bills looms, the agency describes actions it has taken to protect the international supply chain in its Global Engagement report; another report notes the REMS and drug safety studies it has mandated under its postmarket drug safety program.

The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two

FDA is using its new Risk Evaluation and Mitigation Strategy authorities much more frequently in the second year since the law took effect

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts